Two ground-breaking cancer research projects will transform treatment worldwide, thanks to a $7.5 million joint NSW Government and NSW Cancer Council grant.
Chief Cancer Officer and CEO of the Cancer Institute NSW Professor David Currow said the grant will support a trial for targeted radiotherapy technologies for a wide range of cancers and methods to increase access to cutting edge immunotherapy for people with leukaemia and lymphoma.
“This funding will see NSW develop cutting edge treatments that will offer significant global benefits and impact, making personalised radiotherapy treatment and CAR T-cell immunotherapy a possibility for people with cancer in NSW,” Professor Currow said.
“By joining forces with the Cancer Council NSW we are greatly expanding research capacity and expertise in NSW.”
The funding will enable cancer researchers at The University of Sydney to develop and trial more targeted radiotherapy treatment to limit unnecessary tissue damage.
The second project will develop methods for making cutting edge CAR T-cell immunotherapy for leukaemia and lymphoma patients simpler and more affordable.
Professor Karen Canfell, Director of Research at Cancer Council NSW, said CAR T-cell immunotherapy is one of the most exciting therapies to emerge in recent years.
“The challenge now is to ensure CAR T-cell immunotherapy is more available for patients and to fast-track research on expanding it for other cancers.”
Health Minister Brad Hazzard said the collaboration would have a direct impact on people with cancer and cement NSW as a hub for innovative cancer research.
“These two significant cancer projects will potentially help millions of patients around the world by developing more effective, personalised treatments while resulting in significantly reduced side effects,” Mr Hazzard said.
“The NSW Government has invested more than $1 billion in health and medical research across the health system since 2015, demonstrating our dedication to providing a world class, evidence-based health system.
“NSW has made massive inroads in treatments, and now we are focusing on speeding up the time it takes for discoveries to go from the benchtop to the bedside.”